Table of Contents

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Five Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 17

Clinical Trials by Phase in G7 Countries 18

Clinical Trials in G7 Countries by Trial Status 19

Clinical Trials by E7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 20

Clinical Trials by Phase in E7 Countries 21

Clinical Trials in E7 Countries by Trial Status 22

Clinical Trials by Phase 23

In Progress Trials by Phase 24

Clinical Trials by Trial Status 25

Clinical Trials by End Point Status 26

Subjects Recruited Over a Period of Time 27

Clinical Trials by Sponsor Type 28

Prominent Sponsors 29

Top Companies Participating in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials 30

Prominent Drugs 31

Latest Clinical Trials News on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) 32

Nov 11, 2019: Amgen highlights data to be presented on Repatha at AHA 2019 Across Cardiovascular Portfolio 32

Nov 06, 2019: The Medicines company to present inclisiran data from ORION-9 and ORION-10 pivotal phase 3 clinical studies at American Heart Association Scientific Sessions 2019 33

Sep 17, 2019: Arrowhead reports initial data for cardiometabolic candidates 33

Sep 16, 2019: Arrowhead Pharmaceuticals presents initial top-line clinical data and preclinical data on RNAi Candidate ARO-APOC3 34

Clinical Trial Profile Snapshots 35

Appendix 303

Abbreviations 303

Definitions 303

Research Methodology 304

Secondary Research 304

About GlobalData 305

Contact Us 305

Source 306

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019

Summary

GlobalData's clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019" provides an overview of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.